

Table S5. R10046 genotypes distribution according to patients' baseline characteristics

	rs10046			χ^2 p value	Kruskal-Wallis p value
	CC N=229	GT N=450	TT N=207		
BMI, N (%)					
<24	77 (33.6)	135 (30)	75 (36.2)	0.208	
≥24	147 (64.2)	306 (68.0)	125 (60.8)		
Missing	5 (2.2)	9 (2.0)	7 (3.4)		
Tumor size, N (%)					
pT1	139 (60.7)	289 (64.2)	126 (60.9)	0.715	
pT2	72 (31.4)	125 (27.8)	66 (31.9)		
pT3-4	11 (4.8)	28 (6.2)	11 (5.3)		
Missing	7 (3.1)	8 (1.8)	4 (1.9)		
Nodal Status, N (%)					
pN0	110 (48.0)	228 (50.7)	97 (46.9)	0.603	
pN1-3	117 (51.1)	216 (48.0)	107 (51.7)		
Missing	2 (0.8)	6 (1.1)	3 (1.4)		
Grade, N (%)					
G1	37 (16.2)	86 (19.1)	27 (13.0)	0.315	
G2	116 (50.7)	229 (50.9)	121 (58.5)		
G3	55 (24.0)	106 (23.6)	48 (23.2)		
Missing	21 (9.2)	29 (6.4)	11 (5.3)		
Tamoxifen, years (median, IQR)	2.1 (2.0-2.6)	2.2 (1.8-2.5)	2.1 (2.3-2.8)		0.815
Letrozole, years (median, IQR)	3.0 (2.1-5.0)	3.2 (2.-5.0)	3.1 (2.2-5.0)		0.570